State Board of Administration of Florida Retirement System bought a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) during the 2nd quarter, HoldingsChannel reports. The firm bought 16,320 shares of the company’s stock, valued at approximately $175,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Royal Bank of Canada lifted its holdings in Cytek Biosciences by 64.1% in the first quarter. Royal Bank of Canada now owns 5,995 shares of the company’s stock valued at $65,000 after buying an additional 2,341 shares during the period. Metropolitan Life Insurance Co NY lifted its holdings in Cytek Biosciences by 31.5% in the first quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company’s stock valued at $69,000 after buying an additional 1,536 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Cytek Biosciences by 514.7% in the first quarter. Ameritas Investment Partners Inc. now owns 7,567 shares of the company’s stock valued at $82,000 after buying an additional 6,336 shares during the period. Point72 Hong Kong Ltd acquired a new position in Cytek Biosciences in the first quarter valued at $132,000. Finally, Amalgamated Bank acquired a new position in Cytek Biosciences in the first quarter valued at $164,000. Institutional investors and hedge funds own 43.54% of the company’s stock.
Cytek Biosciences Trading Down 1.7 %
Shares of NASDAQ CTKB opened at $14.51 on Wednesday. The firm’s 50-day moving average price is $14.42 and its 200-day moving average price is $12.56. Cytek Biosciences, Inc. has a 1-year low of $7.38 and a 1-year high of $20.57. The firm has a market capitalization of $1.96 billion, a P/E ratio of -1,451.00 and a beta of 0.05.
Insider Buying and Selling
Analysts Set New Price Targets
Several equities analysts recently issued reports on the stock. Piper Sandler boosted their target price on shares of Cytek Biosciences from $16.00 to $18.00 in a report on Monday, November 14th. The Goldman Sachs Group upped their price objective on shares of Cytek Biosciences from $15.00 to $17.00 and gave the company a “buy” rating in a report on Thursday, August 11th. Finally, Morgan Stanley upped their price objective on shares of Cytek Biosciences from $11.00 to $15.00 and gave the company an “equal weight” rating in a report on Friday, August 12th.
About Cytek Biosciences
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.